rs267607326 — VWF Y1146C

Pathogenic missense variant in the VWF D3 domain causing von Willebrand disease type 2A/IIE — the most common D3-cluster mutation — leading to loss of high-molecular-weight multimers, impaired hemostasis, and variable mucocutaneous bleeding

See your personal result for VWF

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

VWF Y1146C — A High-Impact D3 Domain Mutation That Strips Away Clot-Forming VWF

Von Willebrand factor (VWF) is a multimeric glycoprotein essential for primary hemostasis. Under shear stress — in the turbulent flow of small vessels or at a wound site — ultra-large VWF multimers unfurl to capture platelets via their GPIb receptors, forming the platelet plug that stops bleeding before coagulation factors reinforce it. The size of the multimer matters: only the high-molecular-weight (HMW) forms11 high-molecular-weight (HMW) forms
The largest VWF multimers carry the most platelet-binding A1 domains and collagen-binding A3 domains; their loss cannot be compensated by increased total VWF antigen are mechanically competent to bridge platelets to collagen under flow. The Y1146C variant in the D3 domain knocks out precisely those critical large forms, producing von Willebrand disease type 2A/IIE — and it does so in a single heterozygous copy.

The Mechanism

The VWF gene on chromosome 12p13.31 encodes a 2,813-amino-acid pre-pro-protein. After signal peptide cleavage and propeptide removal, mature VWF subunits dimerize and then multimerize22 dimerize and then multimerize
VWF dimerizes head-to-tail via C-terminal CK domain disulfide bonds in the endoplasmic reticulum, then multimerizes head-to-head via N-terminal disulfide bonds — forming chains of 20–40+ subunits stored in Weibel-Palade bodies through precisely orchestrated disulfide bonding in the D3 domain.

The Y1146C substitution introduces a rogue cysteine residue33 introduces a rogue cysteine residue
Tyr1146 is normally a hydroxyl-bearing aromatic residue. Replacing it with cysteine adds a free thiol that forms aberrant disulfide bonds, disrupting local D3 domain folding into the D3 domain — the very region that mediates the initial head-to-head multimerization steps. In vitro expression studies confirm that Y1146C-mutant VWF shows severe reduction in or complete absence of HMW monomers44 Y1146C-mutant VWF shows severe reduction in or complete absence of HMW monomers
Recombinant expression of Y1146C demonstrated intracellular retention of most mutant protein and failure to secrete HMW forms, with decreased secreted VWF antigen levels. The dominant-negative effect of one misfolded allele is sufficient to deplete large multimers from plasma.

The resulting multimer profile is the laboratory hallmark of type 2A VWD: normal or mildly reduced VWF antigen, but complete absence of the large and intermediate multimers on gel electrophoresis. VWF ristocetin cofactor activity (VWF:RCo) is disproportionately reduced relative to antigen — the ratio that distinguishes qualitative defects from simple quantitative deficiency.

The Evidence

Schneppenheim and colleagues55 Schneppenheim and colleagues
Blood 2010, 115:4894–4901; 57 patients from 38 unrelated families with type 2A/IIE multimer pattern identified a cluster of 22 mutations in the VWF D3 domain responsible for a distinct type 2A subgroup (previously described in single families as type IIE). Y1146C was by far the most common, found in 12 of 38 probands (32%). Most mutations in this cluster affect cysteine residues — either creating new cysteines (like Y1146C) or destroying existing ones — consistent with the central role of disulfide bond architecture in D3 domain function. Pathogenicity was confirmed by expression studies and phenotypic characterization of recombinant mutant proteins.

Clinical presentation among Y1146C carriers ranged from mild to severe mucocutaneous bleeding, reflecting the heterogeneity typical of type 2A: epistaxis, easy bruising, prolonged bleeding after dental procedures, heavy menstrual bleeding, and postoperative hemorrhage. The variable expressivity likely reflects contributions from modifier genes, blood type O (which lowers VWF levels by ~25%), and acquired factors.

Therapeutic responsiveness to desmopressin (DDAVP) in type 2A VWD is mutation-dependent66 desmopressin (DDAVP) in type 2A VWD is mutation-dependent
A 2022 study of 250 VWD patients showed only 31% of type 2 patients achieve complete DDAVP response; response is highly variant-specific and can be predicted by genotype. For D3-cluster mutations like Y1146C, even when VWF antigen rises after DDAVP infusion, the released VWF lacks HMW multimers and functional activity remains impaired — making VWF concentrate the preferred treatment modality for this variant.

Practical Actions

The 2021 ASH/ISTH/NHF/WFH guidelines77 2021 ASH/ISTH/NHF/WFH guidelines
Joint guidelines from four major hematology/hemostasis societies providing evidence-based management for all VWD subtypes recommend that type 2A patients requiring hemostasis support receive VWF concentrate rather than desmopressin as first-line therapy, particularly for surgical prophylaxis and major bleeding. Tranexamic acid (an antifibrinolytic) serves as an effective adjunct for mucosal bleeding and minor procedures. Women with heavy menstrual bleeding benefit from hormonal therapy (combined oral contraceptives or progestin-only) or tranexamic acid.

All carriers — including those with mild phenotypes — should have their bleeding history formally assessed and be evaluated by a hematologist experienced in bleeding disorders. A formal DDAVP trial with multimer analysis before and after infusion determines individual responsiveness and informs pre-procedural planning.

Interactions

Blood type O is a significant modifier: O-type individuals have approximately 25% lower VWF levels at baseline, which compounds with the multimer loss from Y1146C to produce more severe bleeding phenotypes. Patients with blood group O and Y1146C may present with more pronounced laboratory abnormalities and symptom burden than AB-type carriers.

Factor V Leiden (rs6025) and the prothrombin G20210A variant (rs1799963) can partially counterbalance a mild bleeding diathesis in Y1146C carriers — though this interaction is theoretical rather than clinically well-documented, and coexisting thrombophilia in a VWD patient complicates management substantially.

Genotype Interpretations

What each possible genotype means for this variant.

TT Non-carrier Normal

Normal VWF D3 domain — full high-molecular-weight multimer assembly

You carry two copies of the common T allele at rs267607326, meaning your VWF D3 domain is intact and your von Willebrand factor assembles normally into the full spectrum of multimers, including the large high-molecular-weight forms essential for platelet adhesion under flow. This is the genotype found in nearly the entire global population. You do not carry the Y1146C von Willebrand disease variant.

CT VWD Type 2A Carrier High Risk

One copy of Y1146C — VWD type 2A/IIE with loss of high-molecular-weight multimers

The Y1146C mutation introduces a novel cysteine in the D3 domain of VWF, which disrupts the disulfide bond architecture required for head-to-head multimerization of VWF subunits. In vitro studies show the mutant protein is largely retained intracellularly with severely reduced secretion of high-molecular-weight forms. In plasma, this produces the type 2A multimer pattern: normal or near-normal VWF antigen but disproportionately reduced VWF activity (ristocetin cofactor, VWF:RCo) and absent large multimers.

Laboratory findings to expect: - VWF antigen (VWF:Ag): may be normal or mildly reduced - VWF activity (VWF:RCo or VWF:GPIbM): significantly reduced relative to antigen - VWF:RCo/VWF:Ag ratio typically below 0.6 (diagnostic of qualitative defect) - Multimer gel: absent large and often intermediate multimers - Factor VIII: may be mildly reduced if VWF levels are low (VWF is the FVIII carrier)

Desmopressin (DDAVP) is frequently ineffective for D3-domain type 2A mutations because the VWF released from Weibel-Palade bodies still lacks HMW multimers. A formal DDAVP trial with pre- and post-infusion multimer analysis is required to determine individual responsiveness before any planned procedure.

Modifier factors affecting symptom severity: - Blood group O lowers baseline VWF antigen by ~25% and worsens phenotype - Age and hormonal status influence VWF levels (levels rise with age, pregnancy, inflammation) - Concurrent platelet disorders can compound bleeding risk

CC VWD Type 2A Homozygous High Risk

Two copies of Y1146C — homozygous type 2A VWD with complete loss of functional VWF multimers

Homozygous pathogenic VWF missense variants are extremely uncommon. For dominant type 2A mutations like Y1146C, biallelic loss of D3 domain function would eliminate all compensatory contribution from a normal allele. In general, compound heterozygosity or homozygosity for type 2A mutations has been associated with more severe phenotypes, sometimes resembling type 3 (near-complete VWF deficiency with both multimer loss and quantitative reduction).

The clinical implications for perioperative and obstetric management would be substantial: all VWF concentrate dosing protocols, monitoring intervals, and prophylaxis thresholds appropriate for severe VWD would apply. This requires dedicated management by a comprehensive hemophilia treatment center.